Company

Stromacare SAS

Stromacare develops cancer immunotherapies using stromal cell modulation for liquid and solid cancers.

About

Founded in 2020, Stromacare is based in Lyon, France, and develops cancer immunotherapies using interstitial regulation and stromal cell modulation. In May 2022, it raised EUR 1.5 million from Crédit Agricole Corporate and Investment Bank, KREAXI and Sham Innovation Santé.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in